Please assess the completion status of the following clinical trial:

Trial Title: Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing SSRF at Denver Health Medical Center~Exclusion Criteria:~* Allergy or hypersensitivity to bupivacaine~* Pregnancy~* Incarceration~* Age \< 18 years~* Indwelling continuous thoracic epidural analgesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bupivacaine indwelling catheter (Type: ACTIVE_COMPARATOR): Bupivacaine indwelling OnQ pain pump catheter will be placed in the subscapular space at the time of surgery, at infusion of 12 ml/hr of 0.25% bupivacaine, and left in place for a maximum of 120 hours
- Liposomal bupivacaine injection (Type: ACTIVE_COMPARATOR): A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).

Based on this trial design, predict the completion outcome and termination type (if applicable).